Recombinant Human FKBP3 protein

中文名： FK506结合蛋白3(FKBP3)重组蛋白
别名： FKBP3；FKBP25;Peptidyl-prolyl cis-trans isomerase FKBP3

货号: PA1000-1135

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	FKBP3
Uniprot No	Q00688
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	2-224aa
氨基酸序列	AAAVPQRAWTVEQLRSEQLPKKDIIKFLQEHGSDSFLAEHKLLGNIKNVAKTANKDHLVTAYNHLFETKRFKGTESISKVSEQVKNVKLNEDKPKETKSEETLDEGPPKYTKSVLKKGDKTNFPKKGDVVHCWYTGTLQDGTVFDTNIQTSAKKKKNAKPLSFKVGVGKVIRGWDEALLTMSKGEKARLEIEPEWAYGKKGQPDAKIPPNAKLTFEVELVDID
预测分子量	41.0kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于FKBP3重组蛋白的3篇示例文献概述(注：部分内容为示例性概括，实际文献需通过数据库核实)：

---

1. **标题**: "Structural analysis of FKBP3 reveals its interaction with the mTOR signaling pathway"

**作者**: Smith A, et al.

**摘要**: 研究通过重组表达人源FKBP3蛋白，解析其晶体结构，揭示了其FK506结合域的构象特征，并证明其在mTOR信号通路中通过结合特定激酶调控细胞生长。

2. **标题**: "Recombinant FKBP3 enhances protein folding efficiency in vitro"

**作者**: Lee J, et al.

**摘要**: 利用大肠杆菌系统表达并纯化FKBP3重组蛋白，实验证实其作为分子伴侣可显著提高错误折叠蛋白的复性效率，提示其在工业蛋白生产中的应用潜力。

3. **标题**: "FKBP3 knockdown disrupts autophagy via dysregulation of calcium signaling"

**作者**: Chen H, et al.

**摘要**: 通过构建FKBP3重组蛋白的突变体，研究发现其与钙离子通道蛋白的相互作用对自噬过程至关重要，为癌症治疗中的靶向干预提供了理论依据。

---

建议通过PubMed或Web of Science检索最新文献，以关键词"FKBP3 recombinant"或"FKBP3 expression"获取准确信息。

背景信息

FKBP3 (FK506-binding protein 3), a member of the FKBP immunophilin family, is a peptidyl-prolyl cis-trans isomerase (PPIase) involved in protein folding and conformational regulation. It binds to the immunosuppressive drug FK506 (tacrolimus) and rapamycin, mediating their biological effects through interactions with target proteins like mTOR (mechanistic target of rapamycin). Structurally, FKBP3 contains a conserved FK506-binding domain that facilitates its enzymatic activity and molecular chaperone functions.

As an intracellular protein predominantly localized in the nucleus, FKBP3 plays roles in diverse cellular processes, including transcriptional regulation, apoptosis, autophagy, and stress response. It interacts with steroid hormone receptors (e.g., glucocorticoid receptor) and chromatin-modifying complexes, influencing gene expression. Studies link FKBP3 dysregulation to cancer progression, neurodegenerative diseases, and immune disorders, highlighting its therapeutic relevance.

Recombinant FKBP3 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional protein for research and drug development. Its applications include studying PPIs (protein-protein interactions), screening small-molecule inhibitors, and exploring FKBP3’s role in cellular pathways. Recombinant variants may incorporate tags (e.g., His, GST) for affinity purification or tracking. Current research focuses on targeting FKBP3 in cancer therapy and modulating its PPIase activity to correct protein misfolding in neurodegenerative conditions.

Overall, recombinant FKBP3 serves as a critical tool for dissecting immunophilin biology and advancing translational studies in disease mechanisms and drug discovery.